ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 571,90
-0,80%
Dow Jones
40 211,72
0,00%
DAX
18 484,94
-0,62%
Brent Oil
82,915
-1,69%
Bitcoin
63 769,02
-1,67%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
03/05/202213h00Business WireTeva Reports First Quarter 2022 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
02/05/202214h00Business WireTeva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent DisputeNYSE:TEVATeva Pharmaceutical Industries Ltd
20/04/202214h54TipRanksTeva Hits FDA Hurdle, Slips 4.5% Pre-MarketNYSE:TEVATeva Pharmaceutical Industries Ltd
20/04/202200h10Dow Jones NewsTeva Pharmaceutical Industries Shares Retreat After FDA Rejection LetterNYSE:TEVATeva Pharmaceutical Industries Ltd
19/04/202223h15Business WireTeva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRMNYSE:TEVATeva Pharmaceutical Industries Ltd
05/04/202213h34PR Newswire (Canada)Teva Canada Charts a New Prescription for CareNYSE:TEVATeva Pharmaceutical Industries Ltd
04/04/202222h05Business WireTeva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022NYSE:TEVATeva Pharmaceutical Industries Ltd
01/04/202214h00Business WireTeva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
31/03/202217h58TipRanksTeva Gains 6.4% on Another Opioid Case SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
30/03/202215h55Dow Jones NewsTeva in Agreement With Florida to Settle Opioid-Related ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
30/03/202215h09Business WireTeva Reaches Agreement With Florida to Settle the State’s Opioid-Related ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
22/03/202212h47TipRanksTeva Settles Opioid Case with Rhode Island, Aims National SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
21/03/202220h45Dow Jones NewsTeva Pharmaceuticals Agrees to Pay Rhode Island $21 Million, Provide Opioid Treatment OptionsNYSE:TEVATeva Pharmaceutical Industries Ltd
21/03/202219h55Business WireTeva Reaches Agreement With Rhode Island to Settle Opioid-Related ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
15/03/202221h03Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NYSE:TEVATeva Pharmaceutical Industries Ltd
08/03/202222h14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202214h00Business WireTeva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
02/03/202213h33PR Newswire (Canada)Teva Canada se réjouit du remboursement d'AJOVY(MD) (frémanezumab)par les régimes publics d'assurance médicaments de l'Alberta, de la Saskatchewan, du Québec ainsi que par le ACC et le Programme SSNA aux patients prescrit AJOVY(MD)NYSE:TEVATeva Pharmaceutical Industries Ltd
02/03/202213h33PR Newswire (Canada)Teva Canada Welcomes Public Drug Plan Reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the Non-Insured Health Benefits Program for Patients prescribed AJOVY® (fremanezumab) for the Preventive Treatment of Migraine in AdultsNYSE:TEVATeva Pharmaceutical Industries Ltd
24/02/202222h11Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
21/02/202214h00PR Newswire (US)Bleichmar Fonti & Auld LLP Announce a Proposed Class Action Settlement Involving Purchasers of Teva Pharmaceutical SecuritiesNYSE:TEVATeva Pharmaceutical Industries Ltd
14/02/202209h00Business WireLa notice de COPAXONE® mentionne désormais son utilisation chez les mères allaitantes atteintes de sclérose en plaques rémittenteNYSE:TEVATeva Pharmaceutical Industries Ltd
14/02/202209h00Business WireCOPAXONE®-Etikett indiziert nun Einsatz für stillende Mütter mit schubförmig verlaufender Multipler SkleroseNYSE:TEVATeva Pharmaceutical Industries Ltd
11/02/202218h26Edgar (US Regulatory)Schedule 13gNYSE:TEVATeva Pharmaceutical Industries Ltd
10/02/202222h16Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NYSE:TEVATeva Pharmaceutical Industries Ltd
10/02/202209h00Business WireCOPAXONE® Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple SclerosisNYSE:TEVATeva Pharmaceutical Industries Ltd
09/02/202222h12Edgar (US Regulatory)Annual Report (10-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
09/02/202213h00Business WireTeva Reports Fourth Quarter and Full Year 2021 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
07/02/202217h01Dow Jones NewsTeva Pharmaceuticals in Deal With Texas Settling Opioid-Related ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
07/02/202216h12Business WireTeva Reaches Agreement With Texas to Settle the State’s Opioid-Related ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

KOSDAQ
076610
Haesung Optics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés